PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Ranok Therapeutics Expands Clinical Testing of CHAMP® BRD4 …
WEBMar 11, 2024 · — Study follows ongoing Phase 1 trial in U.S. and will enroll patients in China to evaluate the first protein degrader developed using Ranok’s innovative CHAMP ® technology. BOSTON, MA, USA & HANGZHOU, China I March 11, 2024 I Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers ...
Inmagene receives IND clearance for IMG-008, a long-acting IL …
WEBFeb 7, 2023 · About IMG-008. IMG-008 is a novel long-acting antagonistic monoclonal antibody targeting IL-36R. Generated from Inmagene’s proprietary QuadraTek ® drug discovery platform, it is being developed to potentially treat auto-inflammatory diseases. IL-36 cytokines belong to the IL-1 family and play an …
Pipeline Database - Pipelinereview
WEBAntibody Target, Technology & Pipeline Database: 1-Year Subscription. 1.600,00€. Any Word All Words Exact Phrase. For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin. Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 ...
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating ...
WEBAug 3, 2022 · At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde ® (irinotecan liposomal injection) ; The clinical study results will be communicated with the regulatory agency
Transposon Announces Final Results from a Phase 2
WEBJul 24, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the …
WEBMar 23, 2024 · OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for early use of combination therapy. 1. The comprehensive PAH portfolio at Johnson & Johnson now includes treatments that address all three foundational and guideline ...
Amberstone Biosciences Secures $12 Million Series A Financing to ...
WEBJan 3, 2022 · LAGUNA HILLS, CA, USA I January 03, 2021 I Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round.The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital ...
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 ...
WEBJul 12, 2024 · The first patient with type 2 diabetes mellitus (T2D) and diabetes-related complications has been enrolled in a clinical trial called DAPAN-DIA in Basel, Switzerland, with Olatec’s NLRP3 inhibitor, dapansutrile, which is sponsored by Principal Investigator, Marc Donath MD
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
WEBJan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.